A Multi-Centre Phase II Study Using Carboplatin AUC-10 for Metastatic Seminoma With IGCCCG Good Prognosis Disease-Therapy Directed by Initial Metabolic Response on PET-CT (Car-PET)

Clinical Trial ID NCT02272816

Rank	Title	Journal	Year	PubWeight™‹?›
1	Toxicity and response criteria of the Eastern Cooperative Oncology Group.	Am J Clin Oncol	1982	43.81
2	Revised response criteria for malignant lymphoma.	J Clin Oncol	2007	22.19
3	Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma.	J Clin Oncol	2007	6.65
4	Sample size tables for exact single-stage phase II designs.	Stat Med	2001	2.31
5	Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial.	J Clin Oncol	1997	1.33
6	A medical research council randomized trial of single agent carboplatin versus etoposide and cisplatin for advanced metastatic seminoma. MRC Testicular Tumour Working Party.	Br J Cancer	2000	1.08
7	Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. London Gynaecological Oncology Group.	J Clin Oncol	1998	0.89
8	Metastatic seminoma treated with either single agent carboplatin or cisplatin-based combination chemotherapy: a pooled analysis of two randomised trials.	Br J Cancer	2004	0.89
9	Carboplatin AUC8 in combination with etoposide and bleomycin in the treatment of intermediate and poor-risk metastatic germ cell tumours: a phase II study.	Cancer Chemother Pharmacol	2001	0.75